GFAP and astrocytoma (excluding glioblastoma): In the first case, we showed that, in GFAP-V12Ha-Ras-bearing mice, expression of Omomyc upon dox administration was able to both prevent the development of astrocytomas and reverse severe neurological symptoms associated with established disease, by decreasing proliferation, increasing apoptosis and causing mitotic defects, therefore reducing astrocytic cell density and increasing mouse survival [67] (Figure 2).